In line with in vitro results, NSUN2 knockdown resulted in a lower rate of tumor formation and reduced tumor burden in subcutaneous xenograft models of gefitinib-resistant H1650 and H1975 cells (Fig. 3f-i). The gene discussed is NSUN2; the disease is neoplasm.